Author Archives: Lindsey Shapiro

Motto Launches Virtual Care App for Autoimmune Diseases

Motto Health has launched an all-in-one virtual health platform to expand access to comprehensive rheumatology care for people with chronic autoimmune conditions, including ankylosing spondylitis . The new app offers virtual rheumatology clinic visits, personalized lifestyle coaching, and symptom tracking, all with the goal of closing the existing…

Group Pilates Superior to At-home Exercise for Patients in Study

An eight-week Pilates group training program for people with ankylosing spondylitis (AS) lowered disease activity, improved spine flexibility, and led to gains in endurance, balance, and quality of life, a recent study showed. Several of these benefits were not seen among those who did an individual at-home exercise program,…

Real-world Study Reveals Side Effects Linked to Cosentyx

Diarrhea, cold-like symptoms, itchy skin, and rash are the most common real-world side effects associated with Cosentyx, an approved treatment for ankylosing spondylitis (AS), a study has found. Such side effects typically emerge in the first month of using the medication, according to the analysis, which included information…

Long-term Brodalumab Treatment for axSpA Supported by Phase 3 Data

Long-term treatment with under-the-skin injections of brodalumab safely and effectively reduced disease activity in people with axial spondyloarthritis (axSpA), according to final data from a Phase 3 trial. axSpA is a type of chronic inflammatory arthritis affecting the joints of the spine, chest, and pelvis. Ankylosing spondylitis (AS) is…

Study’s Machine-learning Algorithm Could Help Diagnose AS Sooner

A new algorithm based on artificial intelligence (AI) could help clinicians reach an earlier diagnosis of akylosing spondylitis (AS), a study found. Using only demographic and clinical data derived from standard blood tests, the method does not require more costly and less widely available imaging techniques, researchers say. The algorithm…

FDA Approves Higher Concentration of Hadlima, a Humira Biosimilar

The U.S. Food and Drug Administration (FDA) has approved a new, more highly concentrated formulation of Hadlima (adalimumab-bwwd), a biosimilar to AbbVie’s Humira (adalimumab), for the treatment of ankylosing spondylitis. As a biosimilar, Hadlima has similar properties, safety, and efficacy to an approved biological treatment, in this…